Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 11:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vehicle Control Gel Clear all
Completed Not applicable Interventional

A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris

NCT01501799
View directory record Official record
Conditions
Acne Vulgaris
Interventions
adapalene 0.1% and benzoyl peroxide 2.5% topical gel, EPIDUO, Placebo (Vehicle Gel)
Drug
Lead sponsor
Actavis Mid-Atlantic LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
8
States / cities
Fremont, California • Miami, Florida • Miramar, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2011 · Synced Sep 17, 2026, 11:25 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers

NCT03588130
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
EscharEx (5% EX-02 formulation), Gel Vehicle, Non-surgical standard of care (NSSOC)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
21
States / cities
Carlsbad, California • Fresno, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2022 · Synced Sep 17, 2026, 11:25 AM EDT
Completed Phase 2 Interventional

CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea

NCT04886739
View directory record Official record
Conditions
Rosacea
Interventions
CGB-400, Vehicle Gel
Drug
Lead sponsor
CAGE Bio Inc.
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 17, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns

NCT02148705
View directory record Official record
Conditions
Thermal Burns
Interventions
NexoBrid, Standard of Care (SOC), Gel Vehicle
Drug · Procedure
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years to 77 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
18
States / cities
Mobile, Alabama • Phoenix, Arizona • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2024 · Synced Sep 17, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

NCT00700063
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005 Topical Gel, Vehicle gel
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
25
States / cities
Hot Springs, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 17, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris

NCT03170388
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-126 Gel, IDP-126 Component A, IDP-126 Component B, IDP-126 Component C, IDP-126 Vehicle Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years to 99 Years
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
29
States / cities
Hot Springs, Arkansas • Fremont, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Sep 17, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris

NCT01880320
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD0271 0.3% / CD1579 2.5%, CD0271 0.1% / CD1579 2.5%, Topical Gel Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
25
States / cities
Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Sep 17, 2026, 11:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate ASN008 Topical Gel (TG)

NCT03798561
View directory record Official record
Conditions
Dermatitis, Atopic, Pruritus, Dermatitis Eczema
Interventions
ASN008 TG, Placebo TG
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
4
States / cities
Cortland, New York • High Point, North Carolina • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Sep 17, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Molluscum Contagiosum Efficacy and Safety Study

NCT04535531
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
SB206 10.3% berdazimer, vehicle gel
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
6 Months and older
Enrollment
891 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
55
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 17, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas

NCT02828111
View directory record Official record
Conditions
Basal Cell Carcinomas
Interventions
Patidegib, Vehicle gel
Drug
Lead sponsor
PellePharm, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Sep 17, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Papulopustular Rosacea Study

NCT01493687
View directory record Official record
Conditions
Papulopustular Rosacea (PPR)
Interventions
CD5024, Azelaic acid 15% Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Rogers, Arkansas • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 17, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris

NCT03003247
View directory record Official record
Conditions
Acne Vulgaris
Interventions
IDP-120 Gel, IDP 120 Component A Gel, IDP 120 Component B Gel, IDP 120 Vehicle Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
364 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
20
States / cities
Encino, California • Lake Mary, Florida • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2017 · Synced Sep 17, 2026, 11:25 AM EDT
Terminated Phase 3 Interventional

Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers

NCT01849965
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
DSC127, placebo vehicle gel, Standard of Care gel, Aquasite
Drug
Lead sponsor
Integra LifeSciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Mesa, Arizona • Phoenix, Arizona • Castro Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 17, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Sofpironium Bromide in Subjects With Axillary Hyperhidrosis (BBI-4000-CL-301)

NCT03836287
View directory record Official record
Conditions
Axillary Hyperhidrosis
Interventions
Sofpironium Bromide Gel, 15%, Vehicle
Drug
Lead sponsor
Botanix Pharmaceuticals
Industry
Eligibility
9 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Rogers, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Sep 17, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis

NCT02336503
View directory record Official record
Conditions
Hyperhidrosis
Interventions
BBI-4000 Gel, 5%, BBI-4000 Gel, 10%, BBI-4000 Gel, 15%, Vehicle
Drug
Lead sponsor
Botanix Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
12
States / cities
Fremont, California • San Diego, California • Aventura, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Sep 17, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum

NCT03436615
View directory record Official record
Conditions
Molluscum Contagiosum
Interventions
SB206 4%, SB206 8%, SB206 12%, Placebo
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
2 Years and older
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
18
States / cities
Scottsdale, Arizona • Santa Ana, California • Thornton, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 17, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Results available

P3 Study in Acne Comparing Once Daily SB204 and Vehicle

NCT02672332
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204 4%, Vehicle Gel
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
9 Years to 99 Years
Enrollment
1,307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
55
States / cities
Anaheim, California • Encinitas, California • Fresno, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 17, 2026, 11:25 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study to Treat Bacterial Vaginosis

NCT01621399
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Product 55394, Placebo Vehicle (non-treatment)
Drug
Lead sponsor
Medicis Global Service Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Mesa, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Sep 17, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris

NCT02242760
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204 2%, SB204 4%, Vehicle Gel
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
20
States / cities
Hot Springs, Arkansas • Encinitas, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Sep 17, 2026, 11:25 AM EDT
Completed Phase 2 Interventional Results available

NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

NCT04435665
View directory record Official record
Conditions
Neurofibromatosis 1, Cutaneous Neurofibroma
Interventions
NFX-179 Gel, Vehicle Gel
Drug
Lead sponsor
NFlection Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Fremont, California • New Brighton, Minnesota • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Sep 17, 2026, 11:25 AM EDT
Not listed Phase 2 Interventional

A Study to Determine the Efficacy of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris

NCT02395549
View directory record Official record
Conditions
Acne Vulgaris
Interventions
0.375% (w/w) MTC896 Gel, 0.75% (w/w) MTC896 Gel, 1.5% (w/w) MTC896 Gel, Vehicle Control Gel
Drug
Lead sponsor
Mimetica Pty Limited
Industry
Eligibility
16 Years to 65 Years
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
20
States / cities
Sacramento, California • San Diego, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Sep 17, 2026, 11:25 AM EDT
Completed Phase 2 Interventional

Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee

NCT01768975
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
OLT1177 Gel, Placebo gel
Drug · Other
Lead sponsor
Olatec Therapeutics, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
DeLand, Florida • South Miami, Florida • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2014 · Synced Sep 17, 2026, 11:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

NCT02576860
View directory record Official record
Conditions
Rosacea
Interventions
CLS001 (Omiganan), Vehicle
Drug
Lead sponsor
Maruho Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
263 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
20
States / cities
Fort Smith, Arkansas • Rogers, Arkansas • Manhattan Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Sep 17, 2026, 11:25 AM EDT
Not yet recruiting Phase 2 Interventional

Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers

NCT06690177
View directory record Official record
Conditions
Venus Leg Ulcers
Interventions
EscharEx (EX-03), Placebo (Gel vehicle)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 17, 2026, 11:25 AM EDT